Kyntra Bio
KYNB
193 hedge funds and large institutions have $2.47B invested in Kyntra Bio in 2018 Q1 according to their latest regulatory filings, with 32 funds opening new positions, 63 increasing their positions, 63 reducing their positions, and 23 closing their positions.
39% more first-time investments, than exits
New positions opened: 32 | Existing positions closed: 23
3% more funds holding
Funds holding: 187 → 193 (+6)
0.12% more ownership
Funds ownership: 2.47% → 2.59% (+0.12%)
0% more repeat investments, than reductions
Existing positions increased: 63 | Existing positions reduced: 63
7% less capital invested
Capital invested by funds: $2.66B → $2.47B (-$192M)
14% less call options, than puts
Call options by funds: $22.7M | Put options by funds: $26.4M
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CS
Credit Suisse
Zurich,
Switzerland
|
+$41.7M |
| 2 |
PC
PointState Capital
New York
|
+$22.2M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$20.2M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$17.9M |
| 5 |
AG
Artal Group
Luxembourg
|
+$13.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$21.9M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
-$19.2M |
| 3 |
Invesco
Atlanta,
Georgia
|
-$9.24M |
| 4 |
Renaissance Technologies
New York
|
-$7.46M |
| 5 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
-$6.87M |
KYNB Hedge Fund Activity: Q1 2018 in Review
193 of the 4,372 institutional investors tracked by Wall St. Rank reported a position in Kyntra Bio (KYNB) for Q1 2018, worth a combined $2.47B — down 7.2% from $2.66B a quarter earlier.
Buyers outnumbered sellers: 32 funds opened new KYNB positions and 23 closed out — a net gain of 9 holders — while 63 added to existing stakes and 63 trimmed.
The largest buyer was Credit Suisse, adding an estimated $41.7M. The largest seller was BlackRock, cutting an estimated $21.9M.
- 193 institutional investors held Kyntra Bio (KYNB) as of Q1 2018, up from 187 in Q4 2017.
- Funds reported $2.47B of Kyntra Bio stock for Q1 2018, down 7.2% quarter-over-quarter.
- 32 funds opened new Kyntra Bio positions in Q1 2018 and 23 closed out, a net change of +9 holders.
- The largest Kyntra Bio buyer in Q1 2018 was Credit Suisse, an estimated $41.7M added.
- The largest Kyntra Bio seller in Q1 2018 was BlackRock, an estimated $21.9M sold.
Based on aggregated 13F filings for Q1 2018.